A citation-based method for searching scientific literature

Ele Ferrannini, Silvia Jimenez Ramos, Afshin Salsali, Weihua Tang, James F List. Diabetes Care 2010
Times Cited: 493



C J Bailey, N Iqbal, C T'joen, J F List. Diabetes Obes Metab 2012
Times Cited: 107




List of shared articles



Times cited



Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes.
Jamie L Benham, Jane E Booth, Ronald J Sigal, Stella S Daskalopoulou, Alexander A Leung, Doreen M Rabi. Int J Cardiol Heart Vasc 2021
0

Effect of sodium-glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis.
Mehmet Kanbay, Laura Tapoi, Carina Ureche, Cem Tanriover, Enes Cevik, Atalay Demiray, Baris Afsar, David Z I Cherney, Adrian Covic. Int Urol Nephrol 2021
0

Dapagliflozin for the treatment of type 2 diabetes mellitus - an update.
Martha K Nicholson, Randa Ghazal Asswad, John Ph Wilding. Expert Opin Pharmacother 2021
0

SGLT1 inhibition boon or bane for diabetes-associated cardiomyopathy.
Jaspreet Kalra, Suresh Babu Mangali, Deepika Dasari, Audesh Bhat, Srashti Goyal, Indu Dhar, Dharamrajan Sriram, Arti Dhar. Fundam Clin Pharmacol 2020
3

Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52-week results from a randomized, open-label, phase III clinical trial.
Eiichi Araki, Hirotaka Watada, Yasuko Uchigata, Osamu Tomonaga, Hitomi Fujii, Hiroshi Ohashi, Tadashi Okabe, Michiko Asano, Fredrik Thoren, Hyosung Kim,[...]. Diabetes Obes Metab 2020
9

Turning Foes to Friends: Knocking Down Diabetes Associated SGLT2 Transporters and Sustaining Life.
Ankit Gupta, Sheenu Mittal, Monika, Richa Dhingra, Neelima Dhingra. Curr Diabetes Rev 2020
0


Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.
Tobias Täger, Dan Atar, Stefan Agewall, Hugo A Katus, Morten Grundtvig, John G F Cleland, Andrew L Clark, Hanna Fröhlich, Lutz Frankenstein. Heart Fail Rev 2020
7

Therapeutic approaches to diabetic cardiomyopathy: Targeting the antioxidant pathway.
Michael Arad, Maayan Waldman, Nader G Abraham, Edith Hochhauser. Prostaglandins Other Lipid Mediat 2020
3




Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis.
Ann M McNeill, Glenn Davies, Eliza Kruger, Stacey Kowal, Tim Reason, Flavia Ejzykowicz, Hakima Hannachi, Nilo Cater, Euan McLeod. Diabetes Ther 2019
7

Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity.
Maria J Pereira, Jan W Eriksson. Drugs 2019
46


Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis.
Jennifer R Donnan, Catherine A Grandy, Eugene Chibrikov, Carlo A Marra, Kris Aubrey-Bassler, Karissa Johnston, Michelle Swab, Jenna Hache, Daniel Curnew, Hai Nguyen,[...]. BMJ Open 2019
60

Cardiovascular Effects of Sodium Glucose Co-transporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus.
Surender Kumar, Pradeep G Talwalkar, Sambit Das, Soumik Goswami. Indian J Endocrinol Metab 2019
1

Assessment of Dapagliflozin Effectiveness as Add-on Therapy for the Treatment of Type 2 Diabetes Mellitus in a Qatari Population.
Rana Moustafa Al AdAwi, Zainab Jassim, Dina Elgaily, Hani Abdelaziz, Bhagya Sree, Mohamed Izham Mohamed Ibrahim. Sci Rep 2019
4